Trials / Completed
CompletedNCT03678818
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
Latrunculin A Supplementation to ICSI Handling Medium
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- Ibn Sina Hospital · Other Government
- Sex
- Female
- Age
- 18 Years – 42 Years
- Healthy volunteers
- Not accepted
Summary
Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Latrunculin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Latrunculin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Medium Supplemented with Latrunculin A | A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate |
Timeline
- Start date
- 2018-09-25
- Primary completion
- 2019-04-20
- Completion
- 2019-04-30
- First posted
- 2018-09-20
- Last updated
- 2019-05-07
Locations
2 sites across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03678818. Inclusion in this directory is not an endorsement.